Breaking News, Collaborations & Alliances

Full-Life Technologies, SK Biopharma Enter $571.5M License Agreement for FL-091

FL-091 is a small-molecule radioligand vector designed to deliver targeted radiation therapy to cancer cells by binding specifically to NTSR1.

Author Image

By: Charlie Sternberg

Associate Editor

Full-Life Technologies, a global radiotherapeutics company, has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life’s FL-091 radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers. FL-091 is a small-molecule radioligand vector designed to deliver targeted radiation therapy to cancer cells by binding specifica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters